Skip to main content
Erschienen in: World Journal of Urology 1/2010

01.02.2010 | Original Article

Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction

verfasst von: Altug Tuncel, Varol Nalcacioglu, Kemal Ener, Yilmaz Aslan, Omur Aydin, Ali Atan

Erschienen in: World Journal of Urology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the efficacy of sildenafil citrate only, 25 mg. Four times/week, tamsulosin only, 0.4 mg once daily, and the combination of both on lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (BPH) and erectile dysfunction.

Methods

A total of 60 men with BPH-related LUTS were randomized to receive sildenafil citrate only (n = 20), tamsulosin only (n = 20), and the combination of both (n = 20) for 8 weeks. Changes from baseline in International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q max), post voiding residual urine volume (PRV), Sexual Health Inventory for Male (SHIM) score, 3rd and 4th questions of International Index of Erectile Function (IIEF) were assessed at the end of the treatment.

Results

The mean age was 58 years. IPSS, Q max, PRV, SHIM scores, and 3rd and 4th questions in IIEF significantly improved in each group. Improvement of IPSS was more remarkable in combination (40.1%) and tamsulosin only (36.2%) groups in comparison with sildenafil citrate only group (28.2%; p < 0.001). Improvement of Q max and PRV were greater in tamsulosin only and combination than sildenafil citrate only group. SHIM scores significantly improved in sildenafil citrate only (65%) and combination (67.4%) than tamsulosin only (12.4%; p < 0.001). Increases in the 3rd and 4th questions of IIEF were greater in sildenafil only and combination than tamsulosin only (p < 0.001).

Conclusions

Treatment with the combination of tamsulosin only and sildenafil citrate only was not superior to tamsulosin only to enhance voiding symptoms. Also, sexual function improvement was similar for both the combination and sildenafil citrate only treatments.
Literatur
1.
Zurück zum Zitat Reynard JM, Peters TJ, Lamond E, Abrams P (1995) The significance of abdominal straining in men with lower urinary tract symptoms. Br J Urol 75:148–153CrossRefPubMed Reynard JM, Peters TJ, Lamond E, Abrams P (1995) The significance of abdominal straining in men with lower urinary tract symptoms. Br J Urol 75:148–153CrossRefPubMed
2.
Zurück zum Zitat Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158:481–487CrossRefPubMed Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158:481–487CrossRefPubMed
3.
Zurück zum Zitat Norman RW, Nickel JC, Fish D, Pickett SN (1994) ‘Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 74:542–550CrossRefPubMed Norman RW, Nickel JC, Fish D, Pickett SN (1994) ‘Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 74:542–550CrossRefPubMed
4.
Zurück zum Zitat Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed
5.
Zurück zum Zitat Girman CJ, Jacobsen SJ, Tsukamato T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428–436CrossRefPubMed Girman CJ, Jacobsen SJ, Tsukamato T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428–436CrossRefPubMed
6.
Zurück zum Zitat Baniel J, Israilov S, Shmueli J, Segenreich H, Livne PM (2000) Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 38:53–58CrossRefPubMed Baniel J, Israilov S, Shmueli J, Segenreich H, Livne PM (2000) Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy. Eur Urol 38:53–58CrossRefPubMed
7.
Zurück zum Zitat Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 12:305–311CrossRefPubMed Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 12:305–311CrossRefPubMed
8.
Zurück zum Zitat Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649CrossRefPubMed Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649CrossRefPubMed
9.
Zurück zum Zitat Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF (2004) Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 63:1148–1152CrossRefPubMed Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF (2004) Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 63:1148–1152CrossRefPubMed
10.
Zurück zum Zitat Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors fort he treatment of male lower urinary tract symptoms. Rev Urol 9:73–77PubMed Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors fort he treatment of male lower urinary tract symptoms. Rev Urol 9:73–77PubMed
11.
Zurück zum Zitat Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I (1998) The evaluation of sexual function in men presenting with benign prostatic hyperplasia. Br J Urol 82:842–846PubMed Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I (1998) The evaluation of sexual function in men presenting with benign prostatic hyperplasia. Br J Urol 82:842–846PubMed
12.
Zurück zum Zitat Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10:14–25PubMed Roehrborn CG (2008) Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol 10:14–25PubMed
13.
Zurück zum Zitat Kaminetsky JC (2006) Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 22:2497–2506CrossRefPubMed Kaminetsky JC (2006) Comorbid LUTS and erectile dysfunction: optimizing their management. Curr Med Res Opin 22:2497–2506CrossRefPubMed
14.
Zurück zum Zitat Andersson KE (2001) Physiology of penile erection. Pharmacol Rev 53:417–450PubMed Andersson KE (2001) Physiology of penile erection. Pharmacol Rev 53:417–450PubMed
15.
Zurück zum Zitat Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2002) Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 59:281–286CrossRefPubMed Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U (2002) Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy men and patients with erectile dysfunction. Urology 59:281–286CrossRefPubMed
16.
Zurück zum Zitat Traish AM, Kim NN, Goldstein I, Moreland RB (1999) Alpha-adrenergic receptors in the penis. Identification, characterization, and physiological function. J Androl 20:671–682PubMed Traish AM, Kim NN, Goldstein I, Moreland RB (1999) Alpha-adrenergic receptors in the penis. Identification, characterization, and physiological function. J Androl 20:671–682PubMed
17.
Zurück zum Zitat Francis SH, Blount MA, Zoraghi R, Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterase, and multi-drug anion transporters. Front Biosci 10:2097–2117CrossRefPubMed Francis SH, Blount MA, Zoraghi R, Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterase, and multi-drug anion transporters. Front Biosci 10:2097–2117CrossRefPubMed
18.
Zurück zum Zitat Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484–2490CrossRefPubMed Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484–2490CrossRefPubMed
19.
Zurück zum Zitat Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R (2006) Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 38:1–12CrossRefPubMed Yassin A, Saad F, Hoesl CE, Traish AM, Hammadeh M, Shabsigh R (2006) Alpha-adrenoreceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 38:1–12CrossRefPubMed
20.
Zurück zum Zitat Andersson KE, Chapple CR, Hofner K (2002) Future drugs for he treatment of benign prostatic hyperplasia. World J Urol 19:436–442PubMed Andersson KE, Chapple CR, Hofner K (2002) Future drugs for he treatment of benign prostatic hyperplasia. World J Urol 19:436–442PubMed
21.
Zurück zum Zitat Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224–229CrossRefPubMed Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O, Sale P, Berardi A, Petrangeli E, Gallucci M, Di Silverio F, Russo MA (1999) Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 189:224–229CrossRefPubMed
22.
Zurück zum Zitat Bing W, Chang S, Hypolite JA, Di Santo ME, Zderic SA, Rolf L, Wein AJ, Chacko S (2003) Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285:F990–F997PubMed Bing W, Chang S, Hypolite JA, Di Santo ME, Zderic SA, Rolf L, Wein AJ, Chacko S (2003) Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 285:F990–F997PubMed
23.
Zurück zum Zitat Deedwania PC (2003) Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diabetes Rep 3:289–292CrossRef Deedwania PC (2003) Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diabetes Rep 3:289–292CrossRef
24.
Zurück zum Zitat Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228–1234CrossRefPubMed Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228–1234CrossRefPubMed
25.
Zurück zum Zitat McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077CrossRefPubMed McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077CrossRefPubMed
26.
Zurück zum Zitat Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy o twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236–1244CrossRefPubMed Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy o twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53:1236–1244CrossRefPubMed
27.
Zurück zum Zitat Kaplan A, Gonzales RR, Te AE (2007) Combination of alfuzosin and sildenafil superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723CrossRefPubMed Kaplan A, Gonzales RR, Te AE (2007) Combination of alfuzosin and sildenafil superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723CrossRefPubMed
28.
Zurück zum Zitat Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178CrossRefPubMed Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 5:2170–2178CrossRefPubMed
29.
Zurück zum Zitat McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401–1407CrossRefPubMed McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401–1407CrossRefPubMed
Metadaten
Titel
Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction
verfasst von
Altug Tuncel
Varol Nalcacioglu
Kemal Ener
Yilmaz Aslan
Omur Aydin
Ali Atan
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2010
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-009-0484-z

Weitere Artikel der Ausgabe 1/2010

World Journal of Urology 1/2010 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.